Guidelines

Society positions, regulatory actions and label changes. Authoritative rather than novel.

Guidelines

Society positions, regulatory actions and label changes.

SEP 9, 2026 · JOURNAL ARTICLE

Gastric Mucosa Cancer Risk: The Operative Link on Gastritis Assessment Staging System

The Korean Journal of Helicobacter and Upper Gastrointestinal Research

A narrative review synthesizing evidence on gastric atrophy staging and risk stratification to inform clinical surveillance strategy and serological monitoring in individual patients.

Expert GuidanceMarta Sbaraglia Esophageal Cancer Research and Treatment Gastric Cancer Management and Outcomes

SEP 9, 2026 · JOURNAL ARTICLE

Recent advances in delivery strategies for CRISPR-based genome editing

Molecular Medicine

A narrative review synthesizing recent advances in CRISPR delivery strategies across research and clinical contexts, offering state-of-the-art overview rather than novel empirical evidence or recommendations.

Expert GuidanceSonghai Tian Qianquan Ma Xiaofen Hua

Study details

DesignNarrative review

JOURNAL ARTICLE

Ecological-collective-flourishing (e-co-flourishing): a framework to guide innovation and research.

The Lancet. Planetary Health

A conceptual framework proposing e-co-flourishing as an integrative approach to wellbeing across human and ecological systems, with illustrative application but no empirical outcome data or comparative evidence.

Expert GuidanceKatrin Wilhelm Verena Hinze Willem Kuyken

JOURNAL ARTICLE

Advances in tuberculosis diagnostics and biomarkers, 2020-26: scientific evidence, recommendations, gaps, and developmental priorities.

The Lancet. Microbe

This is a WHO policy synthesis and scientific evidence review consolidating diagnostic and biomarker advances from 2020–25, informing updated recommendations for TB detection and drug resistance across populations and specimen types.

Expert GuidanceGerhard Walzl Jeremiah Chakaya Suvanand Sahu

JOURNAL ARTICLE

Advances in tuberculosis treatment: novel regimens, new drug pipelines, host-directed therapies, and updated management guidelines.

The Lancet. Microbe

A comprehensive narrative review synthesizing pivotal trial evidence and WHO guideline updates on tuberculosis treatment innovation since 2020, without reporting new primary efficacy data.

Expert GuidanceBen J Marais Simon Tiberi Delia Goletti

Reported

Estimated tuberculosis incidence…10.7 million

Estimated tuberculosis deaths glo…1.23 million

JOURNAL ARTICLE

Minimal supply chain and forecasting testing volumes for clinical bacteriology laboratories in resource-limited settings for individual patient care: a costing study.

The Lancet. Microbe

A costing model informed by expert consensus and real-world data from two African laboratories, providing evidence-based cost estimates and procurement guidance for implementing clinical bacteriology in resource-limited settings, without comparative effectiveness or outcome data.

Expert GuidanceMakeda Semret Jonathon R Campbell Olumide Ajibola

Reported

Consumable cost per hospital admi…$6.23 (5.42–7.54)

Consumable cost per hospital admi…$10.86 (9.82–12.31)

Annual equipment maintenance cost$3,076 (2,840–3,304)

JOURNAL ARTICLE

Advances in development of tuberculosis vaccines and preventive drug therapies: current pipeline, evidence, and access.

The Lancet. Microbe

A narrative review synthesizing current evidence on TB vaccine pipelines and preventive therapies, providing clinical and policy guidance rather than reporting primary efficacy data.

Expert GuidanceBen J Marais Philip Onyebujoh Delia Goletti

Reported

TB vaccine candidates in clinical…6

Total TB vaccine candidates in ac…18

Estimated TB cases in 202410·7 million